Estevo Santamarina

Estevo Santamarina

Auto-generated profile, based on publicly available information

Estevo Santamarina

Epilepsy Unit, Neurology Department, Medicine Department, Universitat Autònoma de Barcelona. Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain; Research group on Status Epilepticus and Acute Seizures, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus, 08035 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2020 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
EFElena Fonseca
Elena Fonseca
MQManuel Quintana
Manuel Quintana
SLSofía Lallana
Sofía Lallana
JRJuan Luis Restrepo
Juan Luis Restrepo
LALaura Abraira
Laura Abraira
MTManuel Toledo
Manuel Toledo

24 August 2021 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
VVVicente Villanueva
Vicente Villanueva
WDWendyl D’souza
Wendyl D’souza
HGHiroko Goji
Hiroko Goji
DKDong Wook Kim
Dong Wook Kim
CLClaudio Liguori
Claudio Liguori
TPThe Permit Pooled Analysis Participants
The Permit Pooled Analysis Participants
The PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study was a pooled analysis of data from 44 real-world studies from 17 countries, in which people with epilepsy (PWE; focal and generalized) were treated with perampanel (PER). Retention and effectiveness were assessed after 3, 6, and 12 months, and at the last visit (last observation carried forward). Effectiveness assessments included 50% responder rate (≥ 50% reduction in seizure frequency from baseline) and seizure freedom rate (no seizures since at least the prior visit); in PWE with status epilepticus, response was defined as seizures under control. Safety and tolerability were assessed by evaluating adverse events (AEs) and discontinuation due to AEs. The Full Analysis Set included 5193 PWE. Retention, effectiveness and safety/tolerability were assessed in 4721, 4392 and 4617, respectively. Retention on PER treatment at 3, 6, and 12 months was 90.5%, 79.8%, and 64.2%, respectively. Mean retention time on PER treatment was 10.8 months. The 50% responder rate was 58.3% at 12 months and 50.0% at the last visit, and the corresponding seizure freedom rates were 23.2% and 20.5%, respectively; 52.7% of PWE with status epilepticus responded to PER treatment. Overall, 49.9% of PWE reported AEs and the most frequently reported AEs (≥ 5% of PWE) were dizziness/vertigo (15.2%), somnolence (10.6%), irritability (8.4%), and behavioral disorders (5.4%). At 12 months, 17.6% of PWEs had discontinued due to AEs. PERMIT demonstrated that PER is effective and generally well tolerated when used to treat people with focal and/or generalized epilepsy in everyday clinical practice.

28 August 2020 in Epilepsia
Verified
Journal Article
Closed access
PDF file
LALaura Abraira
Laura Abraira
ESEstevo Santamarina
Estevo Santamarina
SCSonia Cazorla
Sonia Cazorla
ABAlejandro Bustamante
Alejandro Bustamante
MQManuel Quintana
Manuel Quintana
JSJosé Alvarez Sabín
José Alvarez Sabín

1 July 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ESEstevo Santamarina
Estevo Santamarina
BCBeatriz Parejo Carbonell
Beatriz Parejo Carbonell
JSJacint Sala
Jacint Sala
ÁGÁlvaro Gutiérrez‐Viedma
Álvaro Gutiérrez‐Viedma
JMJúlia Miró
Júlia Miró
MTManuel Toledo
Manuel Toledo

1 December 2020 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
ESEstevo Santamarina
Estevo Santamarina
VBVicente Bertol
Vicente Bertol
VGVanesa Garayoa
Vanesa Garayoa
MGMaría José García-Gomara
María José García-Gomara
IGIñigo Garamendi-Ruiz
Iñigo Garamendi-Ruiz
TCTeresa Casadevall
Teresa Casadevall

Verified
Journal Article
Open access
PDF file
JSJosé Alvarez Sabín
José Alvarez Sabín
ESEstevo Santamarina
Estevo Santamarina
OMOlga Maisterra
Olga Maisterra
CJCarlos Jacas
Carlos Jacas
CMCarlos Molina
Carlos Molina
MQManuel Quintana
Manuel Quintana
Stroke, as the leading cause of physical disability and cognitive impairment, has a very significant impact on patients’ quality of life (QoL). The objective of this study is to know the effect of citicoline treatment in Qol and cognitive performance in the long-term in patients with a first ischemic stroke. This is an open-label, randomized, parallel study of citicoline vs. usual treatment. All subjects were selected 6 weeks after suffering a first ischemic stroke and randomized into parallel arms. Neuropsychological evaluation was performed at 1 month, 6 months, 1 year and 2 years after stroke, and QoL was measured using the EuroQoL-5D questionnaire at 2 years. 163 patients were followed during 2 years. The mean age was 67.5 years-old, and 50.9% were women. Age and absence of citicoline treatment were independent predictors of both utility and poor quality of life. Patients with cognitive impairment had a poorer QoL at 2 years (0.55 vs. 0.66 in utility, p = 0.015). Citicoline treatment improved significantly cognitive status during follow-up (p = 0.005). In conclusion, treatment with long-term citicoline is associated with a better QoL and improves cognitive status 2 years after a first ischemic stroke.